Migraine

>

Latest News

FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention
FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention

April 16th 2025

CT-132 is a 12-week app-based intervention that uses validated behavioral techniques to modulate labile brain circuitry involved in migraine, according to Click Therapeutics.

Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents / image credit ©Lightspring/shutterstock.com
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents

February 27th 2025

Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial

February 25th 2025

FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose

February 6th 2025

New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments image credit ©Parata/stock.adobe.com
New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments

February 5th 2025

<1
...
678910
© 2025 MJH Life Sciences

All rights reserved.